Search research articles
Contact Us
Filters
Showing results (191-200 of 214) with videos related to
Page
of 22
Sort By:
Clinical Pharmacokinetics
|
May 25, 2005
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe
Mireia Segura, Magí Farré, Simona Pichini, et al.
Phytotherapy Research : PTR
|
November 6, 2020
Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis
Ana P Pérez-Acevedo, Roberta Pacifici, Giulio Mannocchi, et al.
Talanta
|
December 10, 2020
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis
Simona Pichini, Sara Malaca, Massimo Gottardi, et al.
Pharmaceuticals (Basel, Switzerland)
|
January 16, 2021
Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
Francesco Paolo Busardò, Ana Pilar Pérez-Acevedo, Roberta Pacifici, et al.
European Journal of Public Health
|
July 17, 2018
A long way to go: 20-year trends from multiple surveillance systems show a still huge use of tobacco in minors in Italy
Giuseppe Gorini, Silvano Gallus, Giulia Carreras, et al.
Biology
|
April 3, 2021
Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users
Nunzia La Maida, Esther Papaseit, Lucia Martínez, et al.
Biology
|
May 28, 2022
New Psychoactive Substances Consumption in Opioid-Use Disorder Patients
Maria Alías-Ferri, Manuela Pellegrini, Emilia Marchei, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 2, 2021
UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations
Sara Malaca, Massimo Gottardi, Federica Pigliasco, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
February 3, 2009
Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: values in selected population of athletes
Rosario Abellan, Rosa Ventura, Ilaria Palmi, et al.
Frontiers in Psychiatry
|
August 22, 2022
Synthetic cannabinoids use in a sample of opioid-use disorder patients
María Alías-Ferri, Manuela Pellegrini, Emilia Marchei, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 214) with videos related to
Sort By:
Page
of 22
Clinical Pharmacokinetics
|
May 25, 2005
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe
Mireia Segura, Magí Farré, Simona Pichini, et al.
Phytotherapy Research : PTR
|
November 6, 2020
Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis
Ana P Pérez-Acevedo, Roberta Pacifici, Giulio Mannocchi, et al.
Talanta
|
December 10, 2020
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis
Simona Pichini, Sara Malaca, Massimo Gottardi, et al.
Pharmaceuticals (Basel, Switzerland)
|
January 16, 2021
Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis
Francesco Paolo Busardò, Ana Pilar Pérez-Acevedo, Roberta Pacifici, et al.
European Journal of Public Health
|
July 17, 2018
A long way to go: 20-year trends from multiple surveillance systems show a still huge use of tobacco in minors in Italy
Giuseppe Gorini, Silvano Gallus, Giulia Carreras, et al.
Biology
|
April 3, 2021
Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users
Nunzia La Maida, Esther Papaseit, Lucia Martínez, et al.
Biology
|
May 28, 2022
New Psychoactive Substances Consumption in Opioid-Use Disorder Patients
Maria Alías-Ferri, Manuela Pellegrini, Emilia Marchei, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 2, 2021
UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations
Sara Malaca, Massimo Gottardi, Federica Pigliasco, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
February 3, 2009
Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: values in selected population of athletes
Rosario Abellan, Rosa Ventura, Ilaria Palmi, et al.
Frontiers in Psychiatry
|
August 22, 2022
Synthetic cannabinoids use in a sample of opioid-use disorder patients
María Alías-Ferri, Manuela Pellegrini, Emilia Marchei, et al.
Page
of 22